12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Fri, 09 Jan 2026 09:55:18 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6InNXcGJGYm9PRmF3c0VOeERRVWUra2c9PSIsInZhbHVlIjoidUd3aEs2K2FFQmU5dGdzYjRRQ3ZnNDVXNFhQZXlSVnRwbWM1a0F1bnBVcitzT0xKMFFEeVZ1QU4yQmNkNkVKRW50dEZLdlVQVXVlbUJEOXBtdENNZWc9PSIsIm1hYyI6IjlkY2M2ZDEwMzBmNjdmMTQ3MzEzMGQ2NThjNTE5YTY4OTVhZDZlODgwMDFiNjA0ZDA4OTU3YWQ5M2M4YTM3ZTEifQ%3D%3D; expires=Mon, 08-Jan-2029 09:55:17 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Sat, 10 Jan 2026 09:55:17 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=6pBgpa%2BHkVg%2F4r1QOBUxAFCotiqACHUof0amC9otmNSzDsW3ViPkHBcfgcS%2Bslm1HpGfrbzqJWFnSZOrMWJzRnqFbcbf3tbLF8VH9fUrjA%3D%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=7,cfOrigin;dur=877 [24] => CF-RAY: 9bb30ee08ed2b82e-LAX [25] => alt-svc: h3=":443"; ma=86400 ) 789

在新冠肺炎疫情席卷全球下，国际均关注就研发疫苗的进度，中国医药集团公司“中国生物”周四晚表示，在新冠肺炎康复者的血浆中，检测出高效价的病毒中和抗体；特免血浆于上周六在中国湖北省武汉市江夏区第一人民医院投入临床，11名重症患者治疗效果显著，实验证明能够有效杀死新冠病毒。

中国生物表示，新冠特免血浆制品是由康复者捐献，含高效价新冠病毒特异性抗体。经严格的血液生物安全性、病毒灭活、抗病毒活性等检测，已成功制备出用于临床治疗的特免血浆。据临床结果反映显示，患者在接受治疗12至24小时后，主要炎症指标明显下降，淋巴细胞比例上升，血氧饱和度、病毒载量等重点指标转好，临床体征和症状明显好转。

有参与研究的专家指出，从临床病理发生过程来看，大部分患者经过治疗康复后，会产生针对新冠病毒的特异性抗体，可杀灭和清除病毒。在缺乏疫苗和特效治疗药物下，采用特免血浆制品治疗新冠肺炎，可大幅降低危重患者的病死率。另倡议其他康复者捐献血浆，其条件包括18至60岁，曾感染过新型冠状病毒，出院后目前身体状况良好。

---

// // // //